Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® Injection for Preferred Access
Friday, December 11, 2015
Source: ABC News Channel 7
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent®(alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, Medicare, and Managed Medicaid patients. Praluent is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies. This decision, when combined with prior favorable coverage decisions at Express Scripts, Aetna and other insurers, provides for access to flexible dosing with Praluent on formularies covering more than 100 million patients in the United States. Praluent is the only PCSK9 inhibitor currently available in two doses, that allows a healthcare provider to adjust the dose based on their patient's LDL cholesterol lowering needs.